Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CDRH stakeholders meeting

This article was originally published in The Gray Sheet

Executive Summary

FDA Associate Commissioner for Strategic Management Linda Suydam and CDRH Director Bruce Burlington are members of an agency panel that will convene at an Aug. 18 public meeting on Sec. 406(b) of the FDA Modernization Act. The meeting, which is mandated under FDAMA, will be divided into three sections, including: Medical Device Users (Part One) and Health Organizations; Trade Associations/Standards Organizations; and Medical Device Users (Part Two) and Patients and Consumers. The meeting begins at 9:00 a.m. in the HHS Humphrey Building in Washington, D.C. FDA will hold a second public meeting on the issue on Sept. 14. For further information, contact Catherine Beck at 301/827-3443

Latest Headlines
See All
UsernamePublicRestriction

Register

MT010454

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel